Results of anti-VEGF treatment for neovascular AMD in eyes with different baseline visual acuity in Turkish population-based on real life data-Bosphorus retina study group.

Humans Angiogenesis Inhibitors / therapeutic use Ranibizumab Vascular Endothelial Growth Factor A Treatment Outcome Visual Acuity Wet Macular Degeneration / drug therapy Photochemotherapy / methods Photosensitizing Agents / therapeutic use Retina Intravitreal Injections Tomography, Optical Coherence / methods Follow-Up Studies Retrospective Studies

Age-related macular degeneration Anti-vascular endothelial growth factor Baseline visual acuity OCT Real-life data

Journal

Photodiagnosis and photodynamic therapy

ISSN: 1873-1597

Titre abrégé: Photodiagnosis Photodyn Ther

Pays: Netherlands

ID NLM: 101226123

Informations de publication

Date de publication:
Jun 2023

Historique:

received: 18 02 2023

revised: 16 04 2023

accepted: 26 05 2023

medline: 3 7 2023

pubmed: 2 6 2023

entrez: 1 6 2023

Statut: ppublish

Résumé

To investigate the anatomical and visual outcomes of the patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (anti-VEGF), according to the baseline best-corrected visual acuity (BCVA) based on the multicenter real-life data. Five-hundred-ninety patients who had taken the Pro Re Nata (PRN) treatment regimen with three loading doses and at least one year of follow-up were included. The patients were divided into three groups according to the baseline BCVA: Group 1 (BCVA ≥ 1.3 Logmar), Group 2 (1.3 Logmar > BCVA ≥ 0.3 Logmar), and Group 3 (BCVA ≤ 0.2 Logmar). BCVA, central macular thickness (CMT), and the number of injections and visits were evaluated. There were 175, 322, and 93 patients in Group 1, Group 2, and Group 3, respectively. The number of visits and injections in the 1st year was not different between the groups (p = 0.58 and p = 0.08) and was 7.09 and 4.41 (Group 1), 6.59 and 5.58 (Group 2), 6.77 and 4.08 (Group 3). There was a significant difference in CMT between the baseline and 12th month in Group 1 and Group 2 (p < 0.001, p < 0.001, respectively) but not in Group 3 (p = 0.84). BCVA was significantly better in the 12th month in Group 1 (p < 0.001), slightly worse in Group 2 (p = 0.79), and significantly worse in Group 3 (p < 0.001). This study provides evidence that an inadequate number of injections cannot protect vision. Moreover, it can cause vision loss, especially in the eyes with good vision.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Five-hundred-ninety patients who had taken the Pro Re Nata (PRN) treatment regimen with three loading doses and at least one year of follow-up were included. The patients were divided into three groups according to the baseline BCVA: Group 1 (BCVA ≥ 1.3 Logmar), Group 2 (1.3 Logmar > BCVA ≥ 0.3 Logmar), and Group 3 (BCVA ≤ 0.2 Logmar). BCVA, central macular thickness (CMT), and the number of injections and visits were evaluated.

RESULTS RESULTS

There were 175, 322, and 93 patients in Group 1, Group 2, and Group 3, respectively. The number of visits and injections in the 1st year was not different between the groups (p = 0.58 and p = 0.08) and was 7.09 and 4.41 (Group 1), 6.59 and 5.58 (Group 2), 6.77 and 4.08 (Group 3). There was a significant difference in CMT between the baseline and 12th month in Group 1 and Group 2 (p < 0.001, p < 0.001, respectively) but not in Group 3 (p = 0.84). BCVA was significantly better in the 12th month in Group 1 (p < 0.001), slightly worse in Group 2 (p = 0.79), and significantly worse in Group 3 (p < 0.001).

CONCLUSION CONCLUSIONS

This study provides evidence that an inadequate number of injections cannot protect vision. Moreover, it can cause vision loss, especially in the eyes with good vision.

Identifiants

DOI: 10.1016/j.pdpdt.2023.103640 PMID: 37263398

pubmed: 37263398

pii: S1572-1000(23)00367-8

doi: 10.1016/j.pdpdt.2023.103640

pii:

doi:

Substances chimiques

Angiogenesis Inhibitors 0

Ranibizumab ZL1R02VT79

Vascular Endothelial Growth Factor A 0

Photosensitizing Agents 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

103640

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.